GeparOcto (GBG 84)

This is a multi-centre, prospective, randomised, open-label phase III trial with two different dose-dense, dose-intensified approaches to neoadjuvant therapy for patients with untreated high-risk, early-stage breast cancer.

Patients will be randomised to one of the following two arms:

ETC arm:

• Epirubicin 150 mg/m² every 2 weeks for 3 cycles, followed by
• Paclitaxel 225 mg/m² every 2 weeks for 3 cycles, followed by
• Cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles.

or
PM(Cb) arm:

• Paclitaxel 80 mg/m² 18 times a week, administered concurrently with
  
• NPLD (Myocet®) 20 mg/m² 18 times a week, administered concurrently with
• Carboplatin AUC 1.5 18 times a week (only for patients with triple-negative breast cancer).